1.Central nervous system mucormycosis after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 6 cases
Juan WANG ; Yingling ZU ; Ruirui GUI ; Zhen LI ; Wenli ZHANG ; Xiangke XIN ; Jian ZHOU
Chinese Journal of Clinical Infectious Diseases 2025;18(4):290-295
Objective:To analyze the clinical characteristics and treatment outcomes of central nervous system(CNS)mucormycosis following allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods:Clinical data of 6 patients diagnosed with CNS mucormycosis after allo-HSCT at Henan Cancer Hospital between January 2020 and December 2024 were retrospectively collected. The patients' clinical manifestations,laboratory findings,imaging features,treatment regimens,and outcomes were analyzed.Results:The incidence of CNS mucormycosis post-allo-HSCT was 0.7%(6/851). The main clinical manifestations included impaired consciousness(5 cases),convulsions(3 cases),headache(2 cases),hemiplegia(1 case),ptosis(1 case),and mydriasis with sluggish light reflex and incomplete eye closure(1 case). The median time from transplantation to the onset of neurological symptoms was 138 days(94-572 days). Metagenomic next-generation sequencing(mNGS)of cerebrospinal fluid identified Rhizopus spp.(2 cases), Rhizomucor spp.(2 cases),and Absidia spp.(2 cases). Cranial MRI performed in five patients revealed multiple mass or patchy lesions in various regions;one patient underwent cranial CT,which showed patchy hypodense lesions in multiple areas. All patients received antifungal therapy,with 2 cases receiving combined intrathecal injection of amphotericin B liposomes;five patients died,and one survived. Conclusions:CNS mucormycosis is a rare but severe complication after allo-HSCT. Its clinical and radiological features are non-specific,posing diagnostic challenges. Intravenous administration of liposomal amphotericin B at full dosage,combined with intrathecal injection,may improve treatment efficacy.
2.BK virus nephropathy after allogeneic hematopoietic stem cell transplantation: a case report and literature review
Wenli ZHANG ; Yingling ZU ; Zhenghua HUANG ; Zhen LI ; Ruirui GUI ; Juan WANG ; Xianjing WANG ; Huili WANG ; Xinxin FAN ; Yongping SONG ; Baijun FANG ; Jian ZHOU
Chinese Journal of Hematology 2025;46(3):273-275
A 20-year-old male patient with T-lymphoblastic lymphoma/leukemia received 9/10 human leukocyte antigen-compatible unrelated peripheral blood stem cell transplantation. He was transplanted with 5.91×10 8 mononuclear cells/kg and 2.88×10 6 CD34 + cells/kg, and neutrophil engraftment was obtained at +11 days and platelet engraftment at +9 days. After transplantation, he presented with repeatedly increased serum creatinine levels, BK virus (BKV) -associated hemorrhagic cystitis, and BKV viremia. BK virus nephropathy was diagnosed based on renal biopsy and metagenomic next-generation sequencing. After adjusting the immunosuppressant, intravenous immunoglobulin, and donor lymphocyte infusion treatment, the patient’s renal function deteriorated progressively, and he eventually died of multiple organ failure at +289 days.
3.BK virus nephropathy after allogeneic hematopoietic stem cell transplantation: a case report and literature review
Wenli ZHANG ; Yingling ZU ; Zhenghua HUANG ; Zhen LI ; Ruirui GUI ; Juan WANG ; Xianjing WANG ; Huili WANG ; Xinxin FAN ; Yongping SONG ; Baijun FANG ; Jian ZHOU
Chinese Journal of Hematology 2025;46(3):273-275
A 20-year-old male patient with T-lymphoblastic lymphoma/leukemia received 9/10 human leukocyte antigen-compatible unrelated peripheral blood stem cell transplantation. He was transplanted with 5.91×10 8 mononuclear cells/kg and 2.88×10 6 CD34 + cells/kg, and neutrophil engraftment was obtained at +11 days and platelet engraftment at +9 days. After transplantation, he presented with repeatedly increased serum creatinine levels, BK virus (BKV) -associated hemorrhagic cystitis, and BKV viremia. BK virus nephropathy was diagnosed based on renal biopsy and metagenomic next-generation sequencing. After adjusting the immunosuppressant, intravenous immunoglobulin, and donor lymphocyte infusion treatment, the patient’s renal function deteriorated progressively, and he eventually died of multiple organ failure at +289 days.
4.Central nervous system mucormycosis after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 6 cases
Juan WANG ; Yingling ZU ; Ruirui GUI ; Zhen LI ; Wenli ZHANG ; Xiangke XIN ; Jian ZHOU
Chinese Journal of Clinical Infectious Diseases 2025;18(4):290-295
Objective:To analyze the clinical characteristics and treatment outcomes of central nervous system(CNS)mucormycosis following allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods:Clinical data of 6 patients diagnosed with CNS mucormycosis after allo-HSCT at Henan Cancer Hospital between January 2020 and December 2024 were retrospectively collected. The patients' clinical manifestations,laboratory findings,imaging features,treatment regimens,and outcomes were analyzed.Results:The incidence of CNS mucormycosis post-allo-HSCT was 0.7%(6/851). The main clinical manifestations included impaired consciousness(5 cases),convulsions(3 cases),headache(2 cases),hemiplegia(1 case),ptosis(1 case),and mydriasis with sluggish light reflex and incomplete eye closure(1 case). The median time from transplantation to the onset of neurological symptoms was 138 days(94-572 days). Metagenomic next-generation sequencing(mNGS)of cerebrospinal fluid identified Rhizopus spp.(2 cases), Rhizomucor spp.(2 cases),and Absidia spp.(2 cases). Cranial MRI performed in five patients revealed multiple mass or patchy lesions in various regions;one patient underwent cranial CT,which showed patchy hypodense lesions in multiple areas. All patients received antifungal therapy,with 2 cases receiving combined intrathecal injection of amphotericin B liposomes;five patients died,and one survived. Conclusions:CNS mucormycosis is a rare but severe complication after allo-HSCT. Its clinical and radiological features are non-specific,posing diagnostic challenges. Intravenous administration of liposomal amphotericin B at full dosage,combined with intrathecal injection,may improve treatment efficacy.
5.Clinical trial of Morinda officinalis oligosaccharides in the continuation treatment of adults with mild and moderate depression
Shu-Zhe ZHOU ; Zu-Cheng HAN ; Xiu-Zhen WANG ; Yan-Qing CHEN ; Ya-Ling HU ; Xue-Qin YU ; Bin-Hong WANG ; Guo-Zhen FAN ; Hong SANG ; Ying HAI ; Zhi-Jie JIA ; Zhan-Min WANG ; Yan WEI ; Jian-Guo ZHU ; Xue-Qin SONG ; Zhi-Dong LIU ; Li KUANG ; Hong-Ming WANG ; Feng TIAN ; Yu-Xin LI ; Ling ZHANG ; Hai LIN ; Bin WU ; Chao-Ying WANG ; Chang LIU ; Jia-Fan SUN ; Shao-Xiao YAN ; Jun LIU ; Shou-Fu XIE ; Mao-Sheng FANG ; Wei-Feng MI ; Hong-Yan ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(6):815-819
Objective To observe the efficacy and safety of Morinda officinalis oligosaccharides in the continuation treatment of mild and moderate depression.Methods An open,single-arm,multi-center design was adopted in our study.Adult patients with mild and moderate depression who had received acute treatment of Morinda officinalis oligosaccharides were enrolled and continue to receive Morinda officinalis oligosaccharides capsules for 24 weeks,the dose remained unchanged during continuation treatment.The remission rate,recurrence rate,recurrence time,and the change from baseline to endpoint of Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Clinical Global Impression-Severity(CGI-S)and Arizona Sexual Experience Scale(ASEX)were evaluated.The incidence of treatment-related adverse events was reported.Results The scores of HAMD-17 at baseline and after treatment were 6.60±1.87 and 5.85±4.18,scores of HAMA were 6.36±3.02 and 4.93±3.09,scores of CGI-S were 1.49±0.56 and 1.29±0.81,scores of ASEX were 15.92±4.72 and 15.57±5.26,with significant difference(P<0.05).After continuation treatment,the remission rate was 54.59%(202 cases/370 cases),and the recurrence rate was 6.49%(24 cases/370 cases),the recurrence time was(64.67±42.47)days.The incidence of treatment-related adverse events was 15.35%(64 cases/417 cases).Conclusion Morinda officinalis oligosaccharides capsules can be effectively used for the continuation treatment of mild and moderate depression,and are well tolerated and safe.
6.Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review
Juan WANG ; Yingling ZU ; Ruirui GUI ; Zhen LI ; Yanli ZHANG ; Jian ZHOU
Chinese Journal of Hematology 2024;45(5):505-508
Systemic mastocytosis (SM) with RUNX1-RUNX1T1 positive acute myeloid leukemia (AML) is a rare myeloid tumor with no standard treatment. Two cases of SM patients with RUNX1-RUNX1T1 positive AML treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation (allo-HSCT) were reported in Henan Cancer Hospital. Mast cell in bone marrow disappeared, C-KIT mutation and RUNX1-RUNX1T1 fusion gene remained negative. Allo-HSCT sequential avapritinib is an effective treatment for SM patients with RUNX1-RUNX1T1 positive AML.
7.The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation
Juan WANG ; Yingling ZU ; Ruirui GUI ; Zhen LI ; Yanli ZHANG ; Jian ZHOU
Chinese Journal of Hematology 2024;45(8):761-766
Objective:To investigate the efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia (CBF-AML) with KIT mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) .Methods:We retrospectively analyzed the clinical data of six patients with molecular biologically positive CBF-AML with KIT mutation after allo-HSCT, who were treated with avapritinib at Henan Cancer Hospital from December 2021 to March 2023, and evaluated the efficacy and safety of avapritinib.Results:After 1 month of treatment with avapritinib, the transcription level of the fusion gene decreased in six patients, and the transcription level decreased by ≥1 log in five patients. In four patients who received avapritinib for ≥3 months, the fusion gene turned negative, and the median time to turn negative was 2.0 (range: 1.0-3.0) months. Up to the end of follow-up, four patients had no recurrence. The most common adverse reaction of avapritinib was myelosuppression, including neutropenia in two cases, thrombocytopenia in two cases, and anemia in one case. The non-hematological adverse reactions were nausea in two cases, edema in one case, and memory loss in one case, all of which were grades 1-2.Conclusion:Avapritinib was effective for molecular biologically positive CBF-AML patients with KIT mutation after allo-HSCT. The main adverse reaction was myelosuppression, which could generally be tolerated.
8.Transcatheter edge-to-edge mitral valve repair for the treatment of mitral valve prolapse with cleft:a case report
Yun-Long MA ; Ming-Jun HE ; Xiang HAO ; Shun WANG ; Xiao-Zhen ZHUO ; Zu-Yi YUAN ; Ke HAN
Chinese Journal of Interventional Cardiology 2024;32(5):284-287
Mitral valve prolapse is one of the common causes of mitral regurgitation.Mitral valve prolapse complicated with leaflet cleft is rare in clinical practice,which most often undergo surgical mitral valve repair or mitral valve replacement.We report a case of mitral valve prolapse with posterior leaflet cleft treated by transcatheter edge-to-edge mitral valve repair,in order to provide a model for similar cases.
9.Antimicrobial activity of a novel R-type phage tail-like bacteriocin against MRSA
Wei TANG ; Ying LIU ; Zhen-Hai TANG ; Ying TANG ; Xin LI ; Jie YAO ; Wei-Zu LI ; Yuan-Hong XU ; Qiang ZHOU
Chinese Pharmacological Bulletin 2024;40(9):1760-1765
Aim To explore the antimicrobial activity of a novel R-type phage tail-like bacteriocin(PTLB)secreted by Enterobacter cloacae SHAMU191747 a-gainst methicillin-resistant Staphylococcus aureus(MR-SA).Methods Antagonistic activity of E.cloacae SHAMU191747 against MRS A was detected by LB agar plate antagonistic test and LB broth micro-fermentation test.The crude extract of fermentation supernatant of E.cloacae SHAMU191747 was prepared by ultra-high-speed centrifugation and density gradient centrifuga-tion.The novel R-type PTLB in the crude extract was detected by transmission electron microscopy.The an-timicrobial activity of the crude extract against MRSA was verified by LB agar plate spot-seeding method.The molecular weight of the novel R-type PTLB was detected by SDS-PAGE electrophoresis.Results E.cloacae SHAMU191747 secreted a novel R-type PTLB,and had a strong antagonistic effect on MRSA.The no-vel R-type PTLB had a molecular weight of approxi-mately 35 ku and could efficiently kill MRSA.The physical dimensions of its tail-sheath-uncontracted functional molecules were(142.7±4.3)×(13.8±0.6)nm,and those of the tail-sheath-contracted non-functional molecules were(57.7±1.2)×(20.8±1.5)nm.Conclusions The novel R-type PTLB pro-duced by E.cloacae SHAMU191747 can efficiently kill MRSA,and has the potential to be developed into a novel antimicrobial drug with great prospects for clini-cal application.
10.Application and evaluation of droplet digital polymerase chain reaction in detection of severe acute respiratory syndrome corona virus-2
CHEN Shuang ; WANG Ming-yue ; ZU Zhen ; TANG Yun ; YE Sheng ; LING Hua ; TAN Zhang-ping
China Tropical Medicine 2023;23(5):495-
Abstract: Objective To analyze the nucleic acid detection results of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) by droplet digital PCR (ddPCR) and compare with the detection results of real-time fluorescence quantitative RT-PCR (qRT-PCR), so as to evaluate the advantages and disadvantages of detection, and to provide data support for optimizing the nucleic acid detection scheme of SARS-CoV-2. Methods According to the SARS-CoV-2 specific primer probe published by the China Center for Disease Control and Prevention, a ddPCR detection method for SARS-CoV-2 was designed. One sample was selected for sensitivity test after gradient dilution; six respiratory virus nucleic acid positive samples including seasonal H3N2 influenza virus and SARS-CoV-2 positive samples were selected for specificity test; five SARS-CoV-2 positive samples were selected for repeatability test; in addition, 30 positive and 20 negative SARS-CoV-2 samples were selected for multiple clinical samples testing, and the results were analyzed and compared with those of qRT-PCR. Results The ddPCR method can specifically detect SARS-CoV-2, and directly obtain the original copy number of the sample target gene to achieve accurate quantification; the sensitivity test of gradient dilution positive samples showed that qRT-PCR detected target genes in part of the 10-5 dilution of samples, and no target genes were detected in 10-6 dilution, while ddPCR detected all target genes in both 10-5 and 10-6 dilution of samples. The detection limit of ddPCR was two orders of magnitude higher than that of qRT-PCR, and the sensitivity was higher than that of qRT-PCR; in the comparison of the repeatability test results of the two methods, the coefficient of variation of ddPCR was 1.266%-11.814%, lower than 1.729%-26.174% of qRT PCR, and the repeatability was higher than qRT-PCR; among 50 clinical samples, 30 positive samples of confirmed cases of Coronavirus Disease 2019 (COVID-19) were detected by both methods, SARS-CoV-2 was successfully detected by both methods, and 20 negative samples of COVID-19 were detected by both methods, and the results were negative, with a coincidence rate of 100.00% (50/50). Conclusion The ddPCR method can accurately quantify SARS-CoV-2 with strong specificity, and its sensitivity and repeatability are higher than those of qRT-PCR, but it also has certain detection limitations and is more suitable for the detection of low load samples. In the actual detection, the two methods can be reasonably combined to improve the detection accuracy.

Result Analysis
Print
Save
E-mail